The ongoing phase 2b SYMMETRY trial evaluated the efficacy of efruxifermin, a fibroblast growth factor 21 (FGF-21) analog, in patients with biopsy-confirmed, compensated cirrhosis (Child-Pugh A) due to MASH [49].The trial enrolled 181 adults, 80% of whom had both obesity and T2DM. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.